Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
In a report released yesterday, Shinichiro Muraoka from Morgan Stanley maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price target of Yen1,500.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Muraoka is an analyst with an average return of -3.9% and a 33.33% success rate. Muraoka covers the Healthcare sector, focusing on stocks such as Astellas Pharma, Shionogi & Co, and SanBio Co.
Astellas Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $12.15.
ALPMF market cap is currently $17.67B and has a P/E ratio of 50.34.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas Pharma Continues Performance-linked Stock Schemes for Executives
- Astellas Pharma Continues Performance-linked Stock Compensation Scheme for 2025
- Astellas Pharma Announces Changes to Board of Directors
- Astellas Pharma Reports Record Revenue and Growth
- Astellas Pharma Reports Higher Than Expected Financial Results
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.